https://www.prnewswire.com/news-releases/shires-shp626-volixibat-receives-fda-fast-track-designation-for-an-investigational-treatment-for-adults-who-have-nonalcoholic-steatohepatitis-nash-with-liver-fibrosis-588636781.html
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for...
/PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track...
fast track designation
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218459
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects...
Interruption of bile acid recirculation through inhibition of the apical sodium-dependent bile acid transporter (ASBT) is a promising strategy to alleviate...
bile acid